2294-46-4

Usage

Uses

Used in Pharmaceutical Industry:
2,2'-iminodipropanol is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its complex-forming ability with metal ions aids in the development of new drugs and formulations.
Used in Surfactant Production:
In the surfactant industry, 2,2'-iminodipropanol is utilized as a chemical intermediate to produce surfactants that have diverse applications in cleaning products, personal care items, and industrial processes.
Used in Water Treatment Chemicals:
2,2'-iminodipropanol is used as a component in the production of water treatment chemicals. Its metal-ion complexing properties contribute to the effectiveness of these chemicals in purifying water and treating wastewater.
Used as a Corrosion Inhibitor in Metalworking Fluids:
2,2'-iminodipropanol is employed as a corrosion inhibitor in metalworking fluids. Its ability to form complexes with metal ions helps protect metal surfaces from corrosion during manufacturing processes.
Used as a Stabilizer in Chlorinated Solvent Production:
In the production of chlorinated solvents, 2,2'-iminodipropanol is used as a stabilizer. This helps maintain the quality and performance of the solvents, ensuring their effectiveness and safety.

Upstream product

• 6168-72-5 2-Amino-1-propanol 
• 116-09-6 hydroxy-2-propanone 
• 6170-23-6 dl-2-amino-1-propanol hydrochloride 
• 75-56-9 methyloxirane 

Downstream Products

• 123-57-9 2,6-dimethylmorpholine 
• 1542268-31-4 meso-3,5-Dimethylmorpholine hydrochloride 
• 402832-69-3 (2S,6S)-2,6-dimethyl-piperazine 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 2815-34-1 2,5-dimethyl-piperazine 
• 59573-44-3 (+)-(2S,5S)-2,5-dimethylpiperazine 

Relevant academic research and scientific papers

Method of preparing new propanolamine

The invention provides a method for preparing MNPA, DNPA and TNPA. The method comprises the following steps: taking PO and ammonium chloride as raw materials for reacting; adding water, ammonium chloride and the PO into a reaction kettle; gradually injecting partial PO while stirring; reacting and synthesizing MNPA.HCL and partial DNPA.HCL under the conditions of temperature at 60-80 DEG C and pressure control lower than or equal to 0.3MPa; separating the MNPA.HCL by utilizing the difference of physical property; injecting the remained PO into filtrate; reacting at 70-100 DEG C; cooling, filtering and drying, thereby obtaining TNPA.HCL; merging the cleaning solution with the filtrate, and then dehydrating, thereby obtaining the DNPA.HCL; and respectively reacting the three hydrochlorides with equivalent methanol alkali, thereby obtaining MNPA, DNPA and TNPA. The method has unique advantages; the relative temperature and pressure are lower during the preparation process; the equipment is simple and is low in investment; the main products are easily separated; the raw material PO is prevented from being subjected to side reactions, such as hydrolyzing into propylene glycol, and the like, under an alkali condition; the energy-saving, emission-reducing, low-carbon and environment-friendly effects are achieved; and the only byproduct sodium chloride is used as a self-use raw material for producing the ammonium chloride and sodium bicarbonate with relative high additional value is obtained.

TRIAZOLYL DERIVATIVES AS SYK INHIBITORS

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

FKBP inhibitors

Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.